Q2 FY27 consolidated: revenue Rs265.85 crore vs 143.59 crore in Q2 FY26; PAT Rs18.57 crore vs 9.43 crore
FREDUN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated revenue from operations for the quarter ended 30 September 2026 rose 85.2 percent to Rs 265.85 crore from Rs 143.59 crore a year earlier; profit after tax rose 96.9 percent to Rs 18.57 crore from Rs 9.43 crore a year earlier. The limited review found no material issue. The Board approved the unaudited quarter and half-year results and proposed an NSE trading application; prior figures were regrouped or recast.
Strong results may support the share price. The NSE listing proposal may broaden investor access and trading activity, subject to approvals.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.